Management of Pneumonia

Initial Assessment and Treatment

The Infectious Diseases Society of America recommends determining pneumonia severity using tools like CURB-65 to guide treatment setting and antibiotic choice 1
Chest radiography is recommended for all patients with suspected pneumonia 2
The Infectious Diseases Society of America suggests obtaining appropriate laboratory tests for hospitalized patients, including complete blood count, renal and liver function tests, and oxygen saturation 2
Blood cultures and sputum samples for Gram stain and culture should be obtained before starting antibiotics in hospitalized patients 2
The American College of Emergency Physicians recommends administering the first antibiotic dose while still in the emergency department for patients being admitted 3

For previously healthy patients, the Infectious Diseases Society of America recommends macrolide, doxycycline, or respiratory fluoroquinolone 2
For penicillin-allergic patients, the Infectious Diseases Society of America suggests respiratory fluoroquinolone 3
The Infectious Diseases Society of America recommends first-line therapy with β-lactam plus a macrolide for non-ICU hospitalized patients 3, 1
For ICU patients, the Infectious Diseases Society of America recommends first-line therapy with β-lactam plus either azithromycin or a fluoroquinolone 3

The British Thoracic Society recommends using oral antibiotics for non-severe pneumonia when there are no contraindications 4
The Infectious Diseases Society of America suggests switching from intravenous to oral therapy when patients are hemodynamically stable, improving clinically, able to ingest medications, and have a normally functioning gastrointestinal tract 3
The Infectious Diseases Society of America recommends treating for a minimum of 5 days, ensuring patient is afebrile for 48-72 hours, and has no more than one CAP-associated sign of clinical instability before stopping antibiotics 3, 1
The British Thoracic Society recommends a standard duration of 7 days for uncomplicated pneumonia 4, 1

The Infectious Diseases Society of America recommends reviewing clinical response daily, including temperature, respiratory and hemodynamic parameters 1
For patients not responding as expected, the British Thoracic Society suggests considering further investigations, including repeat chest radiograph, CRP, white cell count, and additional microbiological testing 4

The Infectious Diseases Society of America recommends treating influenza-associated pneumonia with oseltamivir plus antibacterial agents targeting S. pneumoniae and S. aureus 3
The Infectious Diseases Society of America suggests considering drotrecogin alfa activated within 24 hours of admission for patients with persistent septic shock despite fluid resuscitation 3
The Infectious Diseases Society of America recommends screening hypotensive, fluid-resuscitated patients with severe CAP for occult adrenal insufficiency 3
The American Thoracic Society recommends using low-tidal-volume ventilation for patients with diffuse bilateral pneumonia or ARDS 5

The British Thoracic Society recommends influenza vaccination for high-risk groups, including those with chronic lung, heart, renal and liver disease, diabetes mellitus, immunosuppression, and adults over 65 years 4, 1
The British Thoracic Society suggests considering pneumococcal vaccination for those at increased risk of pneumococcal infection 4, 1

Patients with CAP who demonstrate rapid clinical improvement on IV antibiotics can be safely transitioned to oral therapy and discharged with a shortened course, completing a minimum total of 5 days of antibiotics, provided they meet clinical stability criteria, which includes resolution of vital sign abnormalities, temperature ≤100°F on two occasions 8 hours apart, ability to eat and maintain oral intake, normal mentation, functioning gastrointestinal tract, and decreasing white blood cell count, as recommended by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) 6, 7, 8
The ATS/IDSA guidelines explicitly state that while most patients achieve clinical stability within 48-72 hours, a minimum 5-day course is recommended on a risk-benefit basis, as data supporting courses shorter than 5 days are limited 6, 7

The minimum total duration of therapy is 5 days, even if clinical stability is achieved earlier, as recommended by the ATS/IDSA guidelines 6, 7
Total therapy duration: 5 days is appropriate for most patients without complications, as supported by the ATS/IDSA guidelines 6, 7

When switching from IV to oral antibiotics, use either the same agent or same drug class, as recommended by the ATS/IDSA guidelines 7
Patients can be discharged the same day oral therapy is initiated if clinical stability criteria are met and no unstable comorbidities require continued hospitalization, as supported by the ATS/IDSA guidelines 8

Longer courses (7+ days) are required for pneumonia complicated by meningitis, endocarditis, or other deep-seated infections, suspected or proven MRSA or Pseudomonas aeruginosa, failure to achieve clinical stability within 5 days, or cavitary pneumonia or signs of tissue necrosis, as recommended by the ATS/IDSA guidelines and the Infectious Diseases Society of America (IDSA) 6, 7, 9

Multiple studies demonstrate equivalence of shorter antibiotic courses, including 5 days of IV ceftriaxone vs. 10 days, and 5 days of levofloxacin 750 mg vs. 10 days of 500 mg, as supported by the ATS/IDSA guidelines 6, 7

No routine follow-up chest imaging is needed prior to discharge in clinically improving patients, but follow-up chest radiograph at 4-6 weeks is recommended to establish new baseline and exclude underlying malignancy, particularly in older smokers, as recommended by the ATS/IDSA guidelines 6, 8

The presence of CHF does not alter antibiotic duration recommendations, but ensure that CHF is adequately controlled before discharge, distinguish between pneumonia-related dyspnea and CHF exacerbation, and optimize volume status, as recommended by the ATS/IDSA guidelines 8